Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome | Zendy

Cornelia Then | Zendy; Jobst C. von Einem | Zendy; Daniel Müller | Zendy; Michael J. Flaig | Zendy; Rudolf M. Huber | Zendy; Martín Reincke | Zendy

Open Access

Toxic Epidermal Necrolysis after Pemetrexed and Cisplatin for Non-Small Cell Lung Cancer in a Patient with Sharp Syndrome

Author(s) -

Cornelia Then,

Jobst C. von Einem,

Daniel Müller,

Michael J. Flaig,

Rudolf M. Huber,

Martín Reincke

Publication year - 2012

Publication title -

onkologie

Language(s) - English

Resource type - Journals

eISSN - 1423-0240

pISSN - 0378-584X

DOI - 10.1159/000345109

Subject(s) - pemetrexed , medicine , toxic epidermal necrolysis , lung cancer , dermatology , antifolate , pulmonary toxicity , adenocarcinoma of the lung , erythema , oncology , toxicity , chemotherapy , adenocarcinoma , cisplatin , cancer , antimetabolite

Pemetrexed is an antifolate drug approved for maintenance and second-line therapy, and, in combination with cisplatin, for first-line treatment of advanced nonsquamous non-small cell lung cancer. The side-effect profile includes fatigue, hematological and gastrointestinal toxicity, an increase in hepatic enzymes, sensory neuropathy, and pulmonary and cutaneous toxicity in various degrees.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research